Russia completes early trials of second potential COVID-19 vaccine


NEW DELHI: Russia’s Vector virology institute in Siberia reportedly completed early-stage human trials Tuesday, known as Phase II, of a second potential vaccine against the novel Coronavirus.

Developed by Moscow’s Gamaleya Institute, Russia had registered its first vaccine candidate in August. Late-stage trials of this vaccine were launched last week. The vaccine, Sputnik V, has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the RDIF.

“Today… the final group of 20 volunteers was released from hospital,” watchdog Rospotrebnadzor said in a statement.

“All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.”